Phase 3 study for people with Lung Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 15 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor SystImmune Inc.
Registry number NCT07625644
Started 4 August 2026 Today 16 October 2026 Estimated completion 1 January 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Canberra Hospital Garran ACT Not yet recruiting
Tasman Oncology Southport QLD Not yet recruiting
Flinders Medical Centre Bedford Park SA Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 15 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 550

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)

* Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.

* At least one measurable lesion based on RECIST v1.1 per investigator assessment.

* An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.

* Adequate organ function

Exclusion Criteria:

* Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.

* Participants who have received prior topoisomerase inhibitor-based ADC therapy.

* Participants with history of severe heart disease

* Participants with active autoimmune diseases and inflammatory diseases,

* Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years

* Other protocol-defined inclusion/exclusion criteria apply.

Dates on the record

Started 4 August 2026
Estimated completion 1 January 2030
Registry last updated 15 October 2026
Checked by Voxsanity 15 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 15 October 2026.
  • This page last checked by Voxsanity: 15 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.